Apogee Therapeutics, Inc. Common Stock (APGE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apogee Therapeutics, Inc. Common Stock (APGE) has a cash flow conversion efficiency ratio of -0.044x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-55.57 Million) by net assets ($1.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Apogee Therapeutics, Inc. Common Stock net asset quality index to measure how much of total assets are equity-financed.
Apogee Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Apogee Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore APGE long-term investments to assets to see how much of total assets are deployed in long-term investments.
Apogee Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apogee Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Loongson Technology Corp. Ltd. A
SHG:688047
|
N/A |
|
PGE Polska Grupa Energetyczna SA
WAR:PGE
|
0.025x |
|
Paylocity Holding Corporation
NASDAQ:PCTY
|
0.185x |
|
Hebei Sinopack Electronic Technolog
SHE:003031
|
0.043x |
|
Axalta Coating Systems Ltd
NYSE:AXTA
|
0.028x |
|
Apar Industries Limited
NSE:APARINDS
|
0.031x |
|
ServiceTitan, Inc. Class A Common Stock
NASDAQ:TTAN
|
0.027x |
|
Gerdau S.A
F:GDUA
|
0.028x |
Annual Cash Flow Conversion Efficiency for Apogee Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Apogee Therapeutics, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see Apogee Therapeutics, Inc. Common Stock stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $903.88 Million | $-227.45 Million | -0.252x | -5.37% |
| 2024-12-31 | $716.79 Million | $-171.17 Million | -0.239x | -21.35% |
| 2023-12-31 | $379.91 Million | $-74.76 Million | -0.197x | -70.20% |
| 2022-12-31 | $142.07 Million | $-16.43 Million | -0.116x | -- |
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treat… Read more